Antengene Corporation Limited

Equities

6996

KYG039571008

Biotechnology & Medical Research

Delayed Hong Kong S.E. Other stock markets 01:02:39 2024-05-21 am EDT			5-day change	1st Jan Change
1.01 ^HKD	-3.81%		+4.12%	-49.50%

May. 02	Antengene Logs Slimmer Loss in 2023 Despite Revenue Drop	MT
Apr. 29	Antengene Corporation Limited Announces That Dr. Kan Chen Will Not Offer Himself for Re-Election At the Annual General Meeting	CI

Antengene Corporation Limited Appoints Bo Shan as Chief Scientific Officer

March 25, 2021 at 10:32 am EDT

Antengene Corporation Limited announced that Dr. Bo Shan, Ph.D., has been appointed Chief Scientific Officer (CSO), effective March 26, 2021. As the CSO, Dr. Shan will lead the strategic planning and execution for drug discovery, early development, and CMC, and will directly report to Dr. Jay Mei, Founder, Chairman and CEO of Antengene.

Latest news about Antengene Corporation Limited

Antengene Logs Slimmer Loss in 2023 Despite Revenue Drop	May. 02	MT
Antengene Corporation Limited Announces That Dr. Kan Chen Will Not Offer Himself for Re-Election At the Annual General Meeting	Apr. 29	CI
Antengene Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study	Mar. 20	CI
Antengene's Myeloma Medication Included in China's National Reimbursement Drug List	Dec. 13	MT
Antengene Corporation Limited Announces Successfully Included in 2023 National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance	Dec. 13	CI
Antengene Corporation Limited Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States	Dec. 10	CI
Antengene Announces Xpovio Regulatory Approval in Macau for the Treatment of Relapsed And/Or Refractory Multiple Myeloma	Dec. 06	CI
Antengene Corporation Limited Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day	Nov. 16	CI
Antengene Corporation Limited Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031	23-09-21	CI
Antengene Unaware of Reasons Behind Recent Share Price Drop, Surge in Trade Volume	23-09-18	MT
Antengene Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
Hansoh, Antengene Join Forces for Anti-Tumor Tablet Commercialization in China; Antengene Shares Rise 4%	23-08-10	MT
Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China	23-08-10	CI
Hong Kong Regulator Gives Go Ahead to Antengene’s Application for Multiple Myeloma Drug	23-07-18	MT
Antengene Says Hong Kong Approves Myeloma Drug	23-07-18	MT
Antengene Corporation Limited Announces Xpovio Regulatory Approval in Hong Kong for the Treatment of Relapsed And/Or Refractory Multiple Myeloma	23-07-16	CI
Antengene Announces Xpovio Plus Bortezomib and Dexamethasone Included for Reimbursement by the Pbs in Australia for the Treatment of Relapsed And/Or Refractory Multiple Myeloma	23-05-31	CI
Antengene Corporation Limited Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers	23-05-23	CI
Antengene Corporation Limited Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031	23-05-17	CI
US FDA Clears Perform Trial for Antengene's Tumor Treatment	23-05-17	MT
Antengene Announces Five Presentations At the 2023 American Association for Cancer Research Meeting	23-04-17	CI
Antengene Corporation Limited Announces Board Changes	23-04-14	CI
Antengene Shrinks Loss in 2022 as Revenue Jumps Nearly Sixfold	23-03-28	MT
Antengene Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-28	CI

Chart Antengene Corporation Limited

Duration

Period

More charts

Company Profile

Antengene Corporation Limited is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. The Company is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Companyâs products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The Company mainly conducts its business in Asia-Pacific.

Sector

Biotechnology & Medical Research

Calendar

2024-06-01 - American Society of Clinical Oncology Annual Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Antengene Corporation Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.9741 CNY

Average target price

1.666 CNY

Spread / Average Target

+71.08%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ANTENGENE CORPORATION LIMITED	-49.50%	90.87M
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	115B
REGENERON PHARMACEUTICALS, INC.	+12.41%	107B
ARGENX SE	-2.59%	21.6B
BIONTECH SE	-12.38%	22.31B
GENMAB A/S	-5.29%	19.19B
BEIGENE, LTD.	-3.35%	18.23B
WUXI APPTEC CO., LTD.	-38.57%	17.62B
NEUROCRINE BIOSCIENCES, INC.	+7.51%	14.26B
SAREPTA THERAPEUTICS, INC.	+35.67%	12.37B

Bio Therapeutic Drugs